

Not an actual patient.

PANZYGA co-pay assistance is available for eligible patients

See terms and conditions and other details on the following pages.

panzyga[®]

Immune Globulin
Intravenous (Human) - ifas
10% Liquid Preparation

{ pronounced: *pan-zee-guh* }

INDICATION AND USAGE

PANZYGA (Immune Globulin Intravenous [Human] – ifas) is indicated for the treatment of primary humoral immunodeficiency (PI) in patients 2 years of age and older, chronic immune thrombocytopenia (cITP) in adults and chronic inflammatory demyelinating polyneuropathy (CIDP) in adults. PANZYGA is a liquid medicine for infusion that contains immunoglobulin G (IgG). It is made from human plasma that is donated by healthy people and contains antibodies that replace the missing antibodies in patients with PI or ITP. In patients with CIDP, these antibodies block the body from attacking its own nerve cells.

PANZYGA is given into a vein (intravenously) in a hospital, infusion center, doctor's office, or at home by a trained healthcare provider (HCP).

PANZYGA is a liquid medicine for infusion that contains immunoglobulin G (IgG), which are proteins that help fight infection. PANZYGA is used to treat patients 2 years of age and older with PI, adults with cITP, and adults with CIDP.

SELECTED SAFETY INFORMATION

WARNING: THROMBOSIS, RENAL DYSFUNCTION, and ACUTE RENAL FAILURE

See full prescribing information for complete **BOXED WARNING**

- Thrombosis may occur with immune globulin intravenous (IGIV) products, including PANZYGA. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling vascular catheters, hyperviscosity, and cardiovascular risk factors.
- Renal dysfunction, acute renal failure, osmotic nephropathy, and death may occur with the administration of IGIV products in predisposed patients. Renal dysfunction and acute renal failure occur more commonly in patients receiving IGIV products containing sucrose. PANZYGA does not contain sucrose.
- For patients at risk of thrombosis, renal dysfunction, or acute renal failure, administer PANZYGA at the minimum infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity.

Please click [here](#) for Full Prescribing Information, including complete **BOXED WARNING**.



For eligible patients prescribed PANZYGA, the Pfizer PANZYGA Co-Pay Program is available through participating specialty infusion pharmacies

panzyga[®]
Immune Globulin
Intravenous (Human) - ifas
10% Liquid Preparation



What is PANZYGA?

PANZYGA is a liquid medicine for infusion that contains immunoglobulin G (IgG), which is a protein that helps fight infection. PANZYGA is used to treat patients 2 years of age and older with primary immunodeficiency (PI), adults with chronic immune thrombocytopenia (cITP), and adults with chronic inflammatory demyelinating polyneuropathy (CIDP).



What does the PANZYGA co-pay program provide?

The PANZYGA co-pay program provides eligible, commercially insured patients assistance of **up to \$5000 per calendar year** or the cost of patient's co-pay in a 12-month period (whichever is less) for claims received by the program. Terms and conditions apply. (See terms and conditions on the next page.)



What are the eligibility requirements for the PANZYGA co-pay program?

- Patients must be 2 years or older to be eligible
- Patients must have commercial insurance to be eligible
- Patients are not eligible if they are enrolled in a state or federally funded insurance program (See terms and conditions on the next page.)



Which specialty infusion pharmacies participate in the PANZYGA co-pay program?

All specialty infusion pharmacies may participate in the PANZYGA co-pay program.

READY TO ENROLL? Contact your specialty infusion pharmacy today.

SELECTED SAFETY INFORMATION

Do not use PANZYGA if you:

- Have had a severe allergic reaction to immune globulin or other blood products
- Have a condition called selective (or severe) immunoglobulin A (IgA) deficiency, with antibodies against IgA and a history of hypersensitivity

What should I know before taking PANZYGA?

- PANZYGA can make vaccines (like measles/mumps/rubella or chickenpox vaccines) work less effectively for you. Before you get any vaccines, tell your healthcare provider that you take PANZYGA
- Decreased kidney function and kidney function failure can occur
- Severe headache, drowsiness, fever, painful eye movements, or nausea and vomiting can occur
- Elevated blood pressure can occur particularly in patients who have a history of hypertension (high blood pressure)
- If you are elderly, with heart or kidney problems, discuss with your healthcare provider prior to initiating treatment with PANZYGA
- PANZYGA is made from human blood and therefore may have a risk of transmitting infectious agents, including viruses and, theoretically, the variant Creutzfeldt-Jakob disease (CJD) and CJD agent. The production and manufacturing process reduces this risk, but the risk cannot be eliminated

Please click [here](#) for Full Prescribing Information, including complete BOXED WARNING.

TERMS AND CONDITIONS

By using this co-pay card, you acknowledge that you currently meet the eligibility criteria and will comply with the terms and conditions described below:

Patients are not eligible to use this card if they are enrolled in a state or federally funded insurance program, including but not limited to Medicare, Medicaid, TRICARE, Veterans Affairs health care, a state prescription drug assistance program, or the Government Health Insurance Plan available in Puerto Rico (formerly known as "La Reforma de Salud"). Patient must have private insurance. Offer is not valid for cash paying patients. The value of this co-pay card is limited to a maximum of \$5,000 per calendar year or the cost of patient co-pay in a 12-month period, whichever is less. This co-pay card is not valid when the entire cost of your prescription drug is eligible to be reimbursed by your private insurance plan or other private health or pharmacy benefit programs. You must deduct the value of this co-pay card from any reimbursement request submitted to your private insurance plan, either directly by you or on your behalf. You are responsible for reporting use of the co-pay card to any private insurer, health plan, or other third party who pays for or reimburses any part of the prescription filled using the co-pay card, as may be required. You should not use the co-pay card if your insurer or health plan prohibits use of manufacturer co-pay cards. Patient must be 2 years of age or older to be eligible for the co-pay benefit. Co-pay card cannot be combined with any other savings, free trial or similar offer for the specified prescription. **Co-pay card will be accepted only at participating pharmacies. If your pharmacy does not participate, you may be able to submit a request for a rebate in connection with this offer. This co-pay card is not health insurance.** Offer good only in the U.S. and Puerto Rico. Co-pay card is limited to 1 per person during this offering period and is not transferable. A co-pay card may not be redeemed more than once per 13 days per patient. No other purchase is necessary. No membership fee. Data related to your redemption of the co-pay card may be collected, analyzed, and shared with Pfizer for market research and other purposes related to assessing Pfizer's programs. Data shared with Pfizer will be aggregated and de-identified; it will be combined with data related to other co-pay card redemptions and will not identify you. Pfizer reserves the right to rescind, revoke or amend this offer without notice. Offer expires **12/31/2022**. For more information, call 1-866-642-7606, visit <https://www.pfizer.com/products/product-detail/panzyga> or write: Panzyga Co-Pay Program, P.O. Box 4581 Warren, NJ 07059-0581.

SELECTED SAFETY INFORMATION


PANZYGA can cause serious side effects. If any of the following problems occur after starting PANZYGA, stop the infusion immediately and contact your HCP or call emergency services:

- Hives, swelling in the mouth or throat, itching, trouble breathing, wheezing, fainting, or dizziness. These could be signs of a serious allergic reaction
- Bad headache with nausea, vomiting, stiff neck, fever, drowsiness, painful eye movements, and sensitivity to light. These could be signs of irritation and swelling of the lining around your brain
- Reduced urination, sudden weight gain, or swelling in your legs. These could be signs of a kidney problem (decreased kidney function or kidney failure)
- Pain, swelling, warmth, redness, or a lump in your legs or arms. These could be signs of a blood clot, which could happen in the heart, brain, lungs, or elsewhere in the body
- Brown or red urine, swelling, fatigue, fast heart rate, difficulty breathing, or yellow skin or eyes. These could be signs of a liver or blood problem
- Chest pain or trouble breathing, or blue lips or extremities. These could be signs of a serious heart or lung problem
- Fever over 100°F. This could be a sign of an infection
- Headache, fatigue or confusion, vision problem, chest pain, difficulty breathing, irregular heartbeat, or pounding in your chest, neck, or ears. These could be signs of high blood pressure

Ask your HCP whether you should have rescue medications available, such as antihistamines or epinephrine.

The PANZYGA co-pay program may offer savings

panzyga[®]
Immune Globulin
Intravenous (Human) - ifas
10% Liquid Preparation



Not an actual patient.

Eligible, commercially insured patients may reduce out-of-pocket costs by **up to \$5000 per year*** or the cost of patient's co-pay in a 12-month period, whichever is less.

Contact your specialty infusion pharmacy today to enroll!

*Terms and conditions/eligibility requirements apply. See terms and conditions on the previous page or visit PfizerRxPathways.com.

SELECTED SAFETY INFORMATION

What are the possible or reasonably likely side effects for PANZYGA?

The most common side effects that may occur with PANZYGA are:

- Headache
- Nausea
- Fever
- Increased blood pressure
- Dermatitis
- Fatigue
- Abdominal pain
- Dizziness
- Anemia

These are not all the possible side effects. Talk to your HCP about any side effect that bothers you or that does not go away.

Tell your HCP if you are pregnant, or plan to become pregnant, or if you are nursing.

Patients should always ask their doctors for medical advice about adverse events.

You may report an adverse event related to Pfizer products by calling 1-800-438-1985 (US only). If you prefer, you may contact the US Food and Drug Administration (FDA) directly. The FDA has established a reporting service known as MedWatch where healthcare professionals and consumers can report problems they suspect may be associated with the drugs and medical devices they prescribe, dispense, or use. Visit www.fda.gov/MedWatch or call 1-800-FDA-1088.

PANZYGA[®] is a registered trademark of Octapharma AG.

Please click [here](#) for Full Prescribing Information, including complete **BOXED WARNING**.



octapharma[®]

Manufactured by Octapharma Pharmazeutika Produktionsges m.b.H.
Distributed by Pfizer Labs, Division of Pfizer Inc.